Influence of tumor physiology on delivery of therapeutics

Delivery of Protein and Peptide Drugs in Cancer

Volumn , Issue , 2006, Pages 9-36

  Campbell, Robert B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967495537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860948039_0002     Document Type: Chapter

References (103)

1. Simionescu M, Simionescu N and Palade GE (1974) Morphometric data on the endothelium of blood capillaries. J Cell Biol 60:128-152.
2. Simionescu M, Simionescu N and Palade GE (1978) Structural basis of permeability in sequential segments of the microvasculature. I. Bipolar microvascular fields in the diaphragm. Microvasc Res 15:1-16.
3. Simionescu M, et al. (1985) Differentiated microdomains of the luminal plasmalemma of murine muscle capillaries: Segmental variations in young and old animals. J Cell Biol 100:1396-1407.
4. Ghinea N and Simionescu N (1985) Anionized and cationized hemeundecapeptides as probes for cell surface charge and permeability studies: Differentiated labeling of endothelial plasmalemmal vesicles. J Cell Biol 100:606-612.
5. Simionescu M, Simionescu N and Palade GE (1981) Differentiated microdomains on the luminal surface of the capillary endothelium. I. Partial characterization of their anionic sites. J Cell Biol 90:614-621.
6. Movat HZ (1987) The role of histamine and other mediators in microvascular changes in acute inflammation. Can J Physiol Pharmacol 65(3):451-457.
7. Mylecharane EJ (1990) Mechanisms involved in serotonin-induced vasodilation. Blood Vessels 27(2-5):116-126.
8. Vercellotti GM and Tolins JP (1993) Endothelial activation and the kidney: Vasomediator modulation and antioxidant strategies. Am J Kidney Dis 21(3):331-343.
9. van Hinsbergh VW (2001) The endothelium: Vascular control of haemostasis. Atherosclerosis 95(2):198-201.
10. Hobbs SK, et al. (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612.
11. Yuan F, et al. (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756.
12. Hudson BG, Reeders ST and Trygvason K (1993) Type IV collagen: Structure, gene organization and role in human diseases. J Biol Chem 268:26033-26036.
13. Gorog P and Pearson JD (1985) Sialic acid moieties on surface glycoproteins protect endothelial cells from proteolytic damage. J Pathol 146:205-212.
14. Hallmann R, et al. (2005) Expression of function of laminins in the embryonic and mature vasculature. Physiol Rev 85:979-1000.
15. Sund M, Xie L and Kalluri R (2004) The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS 112(7-8):450-462.
16. Ruoslahti E (1988) Structure and biology of proteoglycans. Annu Rev Cell Biol 4:229-255.
17. Ruoslahti E (2002) Specialization of tumor vasculature. Nat Rev Cancer 2:83-90.
18. Satoh A, et al. (2000) New role of glycosaminoglycans on the plasma membrane proposed by their interaction with phosphatidylcholine. FEBS Lett 477:249-252.
19. Folkman J and Haudenschild C (1980) Angiogenesis by capillary endothelial cells in culture. Trans Ophthalmol Soc UK 100(3):346-353.
20. Michiels C, Arnould T and Remacle J (2000) Endothelial cell responses to hypoxia: Initiation of a cascade of cellular interactions. Biochim Biophys Acta 1497(1):1-10.
21. Charonis AS and Wissig SL (1983) Anionic sites in basement membranes. Differences in their electrostatic properties in continuous and fenestrated capillaries. Microvasc Res 25:265-285.
22. Roberts WG and Palade GE (1997) Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57(4):765-772.
23. Ran S, Downes A and Thorpe PE (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62(21): 6132-6140.
24. Vincent S, DePace D and Finkelstein S (1988) Distribution of anionic sites on the capillary endothelium in an experimental brain tumor model. Microcirc Endoth Lym 1988(4):45-67.
25. Vijayagopal P, Figueoroa JE and Levine EA (1998) Altered composition and increased endothelial cell proliferative activity of proteoglycans isolated from breast carcinoma. J Surg Oncol 68(4):250-254.
26. Denekamp J and Hobson B (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46:711-720.
27. Denekamp J (1984) Vasculature as a target for tumor therapy. Prog Appl Microcirc 4:28-38.
28. David H (1988) Rudolf Virchow and modern aspects of tumor pathology. Pathol Res Pract 183(3):356-364.
29. Goldman E (1907) The growth of malignant disease in man and lower animals with special reference to the vascular system. Lancet 2:1236.
30. Algire GH and Chalkley HW (1945) Vascular reaction of normal and malignant tissues in vitro. I. Vascular reactions fo mice to wounds and to normal and neoplastic implants. J Natl Cancer Inst 6:73-85.
31. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
32. Gimbrone MA, et al. (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261-276.
33. Jain RK and Carmeliet PF (2001) Vessels of death or life. Sci Am 285(6):38-45.
34. Brower V (1999) Tumor angiogenesis-new drugs on the block. Nat Biotechnol 17:963-968.
35. Steege B-t JC, Mayo KH and Griffioen AW (2001) Angiostatic proteins and peptides. Crit Rev Eukar Gene 11(4):319-334.
36. Ausprunk DH and Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14(1):53-65.
37. Madri JA and William SK (1983) Capillary endothelial cell cultures: Phenotypic modulation by matrix components. J Cell Biol 97:153-165.
38. Morikawa S, et al. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160(3):985-1000.
39. Hirschi KK and D’Amore PA (1996) Pericytes in the microvasculature. Cardiovasc Res 32(4):687-698.
40. Jain RK (1987) Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6:559-593.
41. Jain RK (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9:253-266.
42. Jain RK (1988) Determinants of tumor blood flow: A review. Cancer Res 6:559-594.
43. Pluen A, et al. (2001) Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. PNAS 98(8):4628-4633.
44. Renkin EM (1985) Transport of macromolecules: Pores and other endothelial pathways. Appl Physiol 58:315-325.
45. Dellian M, et al. (2000) Vascular permeability in a human tumor xenograft: Molecular charge dependence. Br J Cancer 82(9):1513-1518.
46. Zhao XB and Lee RJ (2004) Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 56(8):1193-204.
47. Yoshida J, Mizuno M and Wakabayashi T (2004) Interferon-beta gene therapy for cancer: Basic research to clinical application. Cancer Sci 95(11):858-865.
48. Xu L, et al. (2001) Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 7(10):723-734.
49. McLean JW, et al. (1997) Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol 273(1 pt 2):387-404.
50. Thurston G, et al. (1998) Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Inves 101(7):1401-1413.
51. Campbell RB, et al. (2002) Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62:6831-6836.
52. Aukland K and Reed RK (1993) Interstitial-lymphaticmechanisms in the control of extracellular fluid volume. Physiol Rev 73(1):1-78.
53. Young JS, Lumsden CE and Stalker AL (1950) The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue on the rabbit. J Pathol Bacteriol 62(3):313-333.
54. Butler TP, Grantham FH and Gullino PM (1975) Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res 35(11 pt 1):3084-3088.
55. Boucher Y, Leunig M and Jain RK (1996) Tumor angiogenesis and interstitial hypertension. Cancer Res 56(18):4264-4266.
56. Boucher Y, et al. (1991) Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51(24):6691-6694.
57. Sevick EM and Jain RK (1989) Geometric resistance to blood flow in solid tumors prefused ex vivo: Effects of tumor size and perfusion pressure. Cancer Res 49(13):3506-3512.
58. Zlotecki RA, et al. (1995) Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: Network analysis and mechanistic interpretation. Microvasc Res 50:429-443.
59. Zlotecki RA, et al. (1993) Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res 53:2466-2468.
60. Less JR, et al. (1997) Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 4(1):25-33.
61. Milosevic M, et al. (2001) Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygenation measurements. Cancer Res 61:6400-6405.
62. Jain RK, Munn LL and Fukumura D (2002) Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2(4):266-276.
63. Brown EB, et al. (2001) In vivo measurement of gene expression, angiogenesis, and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 7(7):864-868.
64. Hlatky L, Hahnfeldt P and Folkman J (2002) Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn’t tell us. J Nat Cancer Inst 94(12):883-893.
65. Folkman J (2002) Looking for a good endothelial address. Cancer Cell 2:113-115.
66. Ferrara N and Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25.
67. Dvorak HF, et al. (1995) Vascular permeability factor/vascular endothelial growth factor,microvascular hyperpermeability and angiogenesis. Am J Pathol 146:1029-1039.
68. Senger DR, et al. (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Metastasis Rev 12:303-324.
69. Yuan F, et al. (1994) Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356.
70. Brown LF, et al. (1997) Vascular permeability factor/vascular endothelial growth factor: A multi functional angiogenic cytokine, in Rosen IDGEM (ed.), Regulation of Angiogenesis, Birkhauser Verlag Basel/Switzerland.
71. Liotta LA, Rao CN and Barsky SH (1983) Tumor invasion and the extracellular matrix. Lab Invest 49(6):636-649.
72. Marhava R and Zoller M (2004) CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 35(3):211-231.
73. Woessner JF, Jr (1968) Biological membranes of tissue resorption, in BSG (ed.), Treatise on Collagen, Academic Press: New York, pp. 253-330.
74. Woessner JF, Jr (1998) The matrix metalloproteinase family, in WCPa RPM (eds.), Matrix Metalloproteinases, Academic Press, San Diego: pp. 1-14.
75. Agnantis NJ, et al. (2004) Tumormarkers in cancer patients.An update of their prognostic significance. Part II. In Vivo 18(4):481-488.
76. Itoh T, et al. (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58(5):1048-1051.
77. Timpl R, et al. (1978) Nature of the collagenous protein in a tumor basement membrane. Biochem Biophys Res Comm 84(43).
78. Timpl R, et al. (1985) Structure and biology of the globular domain of basement membrane type IV collagen. Ann NY Acad Sci 460:58-72.
79. Hernandez MA and Amenta PS (1979) The basement membrane in pathology. Lab Invest 48:656-680.
80. Uhm JH, et al. (1997) Mechanisms of glioma invasion: Role of matrix metalloproteinases. Can J Neurol Sci 24(1):3-15.
81. Stuve O, et al. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann Neurol 40(6): 853-863.
82. Hamano Y, et al. (2003) Physiological levels of tumstatin, a fragment of collagen IV alphaVbeta3 integrin. Cancer Cell 3:589-601.
83. Pasco S, et al. (2004) In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res 301:251-265.
84. Gribbon PM, et al. (1998) in Reed RK and Rubin K (eds.), Connective Tissue Biology: Integration and Reductionism, Portland, London, pp. 95-124.
85. Brown E, et al. (2003) Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 9(6):796-800.
86. Binder C, et al. (2004) Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat 2004(87):157-166.
87. Hong Z, et al. (1995) Enhanced adeno-associated virus vector expression by adenovirus protein-cationic liposome complex. Chinese Med J 108(5): 332-337.
88. Anwer K, et al. (2004) Peptide-mediated gene transfer of cationic lipid/plasmid DNA complexes to endothelial cells. J Drug Target 12(4):215-221.
89. Yuan X, et al. (2003) Lipid-mediated delivery of peptide nucleic acids to pulmonary endothelium. Biochem Biophys Res Comm 302(1):6-11.
90. Sauer I, et al. (2005) An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochem 44(6):2021-2029.
91. Nikol S, et al. (2002) Local perivascular application of low amountsof a plasmid encoding for vascular endothelial growth factor (VEGF165) is efficient for therapeutic angiogenesis in pigs. Acta Physiol Scand 176(2):151-159.
92. Monsky WL, et al. (1999) Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59(16):4129-4135.
93. Salnikov AV, et al. (2005) Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 5(4):512-521.
94. Kristensen CA, et al. (1996) Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 74(4): 533-536.
95. Taghian A, et al. (2005) Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical implications. J Clin Oncol 23(9):1951-1961.
96. Kristjansen PE, Boucher Y and Jain RK (1993) Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 53(20):4764-4766.
97. Lee I, et al. (1994) Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline. Br J Cancer 69(3):492-496.
98. 2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther 296(2):632-641.
99. Griffon EG, et al. (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors. Cancer Res 59:3776-3782.
100. Pietras K, et al. (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484.
101. Peters CE, Chaplin DJ and Hirst DG (1997) Nicotinamide reduces tumour interstitial fluid pressure in a dose- and time-dependent manner. Br J Radiol 70:160-167.
102. Rubin K, et al. (2000) Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralled by and increase uptake of (51) Cr-EDTA. Int J Cancer 86(5):636-643.
103. Ansiaux R, et al. (2005) Thalidomide radiosensitizes tumor through early changes in the tumor microenvironment. Clin Cancer Res 11:743-750.